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Novelty and Impact 
While observational studies have suggested an association between blood cholesterol levels 
and colorectal cancer (CRC), they do not establish causality and may be influenced by 
confounding factors. Here we use Mendelian randomisation using genetic instrumental 
variables to provide evidence for a causal link between blood cholesterol levels and colorectal 
cancer. Thus, reducing hyperlipidaemia is an important target for primary prevention of CRC 
in the population. 
 
ABSTRACT 
 
While elevated blood cholesterol has been associated with an increased risk of colorectal 
cancer (CRC) in observational studies, causality is uncertain. Here we apply a Mendelian 
randomisation (MR) analysis to examine the potential causal relationship between lipid traits 
and CRC risk. We used single nucleotide polymorphisms (SNPs) associated with blood levels 
of total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and high-density 
lipoprotein (HDL) as instrumental variables (IV). We calculated MR estimates for each risk 
factor with CRC using SNP-CRC associations from 9,254 cases and 18,386 controls. Genetically 
predicted higher TC was associated with an elevated risk of CRC (odds ratios (OR) per unit SD 
increase = 1.46, 95% confidence interval [CI]: 1.20-1.79, P=1.68x10-4). The pooled ORs for LDL, 
HDL, and TG were 1.05 (95% CI: 0.92-1.18, P=0.49), 0.94 (95% CI: 0.84-1.05, P= 0.27), and 0.98 
(95% CI: 0.85-1.12, P=0.75) respectively. A genetic risk score for 3-hydoxy-3-methylglutaryl-
coenzyme A reductase (HMGCR) to mimic the effects of statin therapy was associated with a 
reduced CRC risk (OR=0.69, 95% CI: 0.49-0.99, P=0.046). This study supports a causal 
relationship between higher levels of TC with CRC risk, and a further rationale for 
implementing public health strategies to reduce the prevalence of hyperlipidaemia. 
INTRODUCTION 
 
Colorectal cancer (CRC) is the third most common cancer diagnosed in economically 
developed countries1. The mortality rate from CRC has been declining over the last twenty 
years as a consequence of improved medical care and probably through the introduction of 
population screening programs for the early detection of tumours2-4. Despite this 
improvement in patient outcome, it is still important to understand the risk factors for CRC in 
order to inform public health policy.  
 
A number of factors influenced by lifestyle have been reported to be associated with the 
development of CRC in epidemiological observational studies, including a positive correlation 
with circulating levels of plasma cholesterol and other components of the lipid profile5, 6. It is, 
however, unclear from these studies if findings reflect a causal relationship or are simply a 
consequence of confounding by factors common to the aetiology of both CRC and 
hyperlipidaemia (e.g. common dietary factors) or reverse causality. Because lipid levels can 
be modified by lifestyle and treatment with statins, deciphering the basis for the association 
should be informative in formulating and optimizing prevention programs for CRC.   
 
Evidence that statin use will effect a reduction in CRC is highly controversial7, 8. Although an 
analysis of The Health Improvement Network (THIN) database found that statin usage was 
associated with reduced CRC (long term usage: odds ratio [OR] = 0.95, 95% confidence interval 
[CI]: 0.91-0.99; short term usage: OR= 0.92, 95% CI: 0.85-0.99); no difference was shown 
between continued versus discontinued therapy, suggesting indication bias8. Moreover a 
recent meta-analysis of data from eight randomized controlled trials (RCTs) failed to 
demonstrate a beneficial effect which was statistically significant (relative risk = 0.89, 95% CI: 
0.74-1.07)9. Each of these RCTs, however have the same limitations of short follow-up time, 
few CRC cases, and ascertainment of CRC as a secondary outcome.  
 
Mendelian randomisation (MR) provides a useful complement  to the traditional 
epidemiological study10. This strategy makes use of genetic variants that are robustly 
associated with traits of interest, in this case lipid traits - total cholesterol (TC), low‐density 
lipoprotein (LDL), high‐density lipoprotein (HDL), and triglyceride (TG) - as instrumental 
variables (IV) to infer whether associations between exposure and disease are causal. The use 
of genetic variants as IV to proxy modifiable exposure therefore avoids confounding by 
environmental factors, can be reflective of life-long exposure (propensity), and is not be 
subject to reverse causality. The strength of the IV in MR is important for power, but weak 
instruments can also lead to inconsistent instrumental variables estimators. Hence using a 
genetic score derived from a combination of single nucleotide polymorphisms (SNPs), which 
collectively explains more of the variance in the risk factor, mitigates against weak instrument 
bias thereby increasing study power.  
 
Genetics scores derived from multiple SNPs for lipid traits have been used in MR studies to 
investigate associations between blood lipids and coronary heart disease11, and most recently 
prostate cancer12. Here we have employed MR to examine the impact of lipid traits on the 
risk of developing CRC.  
 
  
METHODS 
 
Colorectal cancer datasets  
We investigated the relationship between genetic risk scores for lipid traits and CRC risk using 
data from seven previously reported genome-wide association studies (GWAS) of CRC13 
(Table 1). Briefly, these GWAS were all based on individuals with European ancestry and 
comprise: CCFR1, CCFR2, COIN, FINLAND, UK1, Scotland1 and VQ58. All studies were 
approved by their respective institutional review boards and conducted with appropriate 
ethical criteria in each country and in accordance with the Declaration of Helsinki. 
Comprehensive details on the cases and controls are available in previously published work13-
16. 
 
Genotyping data 
Details of the genotyping and quality control of the seven CRC GWAS have been previously 
published13. Briefly, we excluded SNPs with a minor allele frequency of <1%, low call rate 
<95%, SNPs violating Hardy-Weinberg equilibrium, and individuals with non-European 
ancestry as assessed using HapMap v2 reference data17. Imputation of untyped SNP 
genotypes was performed using IMPUTEv2 software18 using a merged reference panel 
consisting of Sequencing Initiative Suomi (for the FINLAND data) or UK10K (for the remaining 
data) in addition to 1000 Genomes Project data. Poorly imputed SNPs (i.e. INFO score of <0.8) 
were excluded. Summary statistics from the seven GWAS were used to calculate the ORs for 
lipid-related SNPs. 
 
Gene variants used to construct genetic risk scores 
Genetic risk scores as IVs for circulating lipid fractions were developed from SNPs previously 
identified by the Global Lipids Genetics Consortium (GLGC)19. Median and range of standard 
deviations of lipid trait measurements in European cohorts of the Global Lipids Genetics 
Consortium are shown in Supplementary Table 1. We considered only SNPs associated at 
genome-wide significance (i.e. P ≤ 5.0x10-8) and restricted to individuals with European 
Ancestry. To avoid co-linearity between SNPs, we excluded SNPs that were correlated (i.e. r2 
value ≥ 0.01), only considering the SNP with the strongest effect on the lipid trait for inclusion 
in genetic risk scores. Pairwise r2 values were calculated using PLINK v1.90 utilising samples 
of European ancestry from the 1000 Genomes and UK10K sequencing projects 
(Supplementary Data). This resulted in 58 SNPs for HDL, 29 SNPs for LDL, 26 SNPs for TG, and 
38 SNPs for TC (Supplementary Table 2). Because lipid traits share common genetic variants, 
in addition to calculating an ‘unrestricted allele score’ that included all SNPs associated with 
the lipid trait, we also calculated a ‘restricted allele score’ as per Holmes et al 11 based on SNPs 
exclusively associated with HDL (n=43), LDL (n=9), or TG (n=14) to make them as specific as 
possible (Supplementary Table 3). Risk alleles were those that were positively associated with 
TC, LDL and TG or negatively associated with HDL levels. For all identified SNPs, we recovered 
the chromosome positions, the risk alleles, association estimates and standard errors.  
 
Statistical analysis 
We performed MR analysis to assess the association between TC, LDL, HDL, TG and CRC using 
summary statistics as described Burgess et al. (2015) 20. The combined ratio estimate (β̂) of 
all SNPs associated with each lipid trait on CRC was calculated under a fixed-effects model: 
β̂ =  
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Xk corresponds to the association between SNP k with the lipid trait and Yk is the association 
between SNP k and CRC risk with standard error 𝜎𝑌𝑘 . The standard error of the combined ratio 
estimate is given by:  
se(β̂) =  √
1
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   . 
With the statistics generated by following these calculations on the seven different cohorts in 
the CRC data, we performed a meta-analysis under a fixed-effects model to derive the final 
ORs and confidence intervals.  
 
A key assumption for this MR analysis is there is no pleiotropism (i.e. a gene influencing 
multiple traits) between the genes influencing CRC and the lipid traits under study. Therefore, 
before performing the MR analysis, we performed LD regression to test for global evidence 
of pleiotropy as per Bulik-Sullivan et al. (2015) 21, 22, and subsequently implemented an MR-
Egger regression to examine for violation of the standard IV assumptions in our analysis 23. 
 
For each statistical test we considered a global significance level of P≤0.05 as being 
satisfactory to derive conclusions. To assess the robustness of our conclusions, we imposed a 
conservative Bonferroni-corrected significance threshold of 0.0125 (i.e. 0.05/4 lipid traits). 
We deemed a P-value > 0.05 as non-significant (i.e. no association), a P-value ≤0.05 as 
evidence for a potential causal association, and a P-value ≤0.0125 as significant evidence for 
a causal association. All statistical analyses were undertaken using R software (Version 
2.14.1). 
 
The power of a MR investigation depends greatly on the proportion of variance in the risk 
factor that is explained by the IV. We estimated study power using the methodology of 
Burgess (2014) 24, utilizing published estimates of the heritability of lipid trait associated IV 
SNPs 19 and the reported effect of each trait on CRC risk in epidemiological studies 8. 
 
In a subsidiary analysis we constructed a genetic risk score for 3‐hydroxy‐3‐methylglutaryl‐
CoA reductase (HMGCR) using rs12916, rs17238484, rs5909, rs2303152, rs10066707 and 
rs2006760. These specific SNPs have previously been used to mimic statin intervention to 
estimate a  causal association of statin use and coronary heart disease and diabetes 25. 
RESULTS 
 
Using LD regression, we found no evidence for global pleiotropism (i.e. shared genetic 
components) between CRC and any of the lipid traits under investigation (Table 2). Following 
on from these observations we performed MR-Egger regression tests to explicitly examine for 
infringement of the standard instrumental variable assumptions in our MR analysis. We did 
not find evidence of any violation in respect to TC, LDL, HDL or TG (Table 2, Supplementary 
Figure 1). In view of the totality of these findings we were reassured of the validity of our MR-
based analysis to infer whether the relation between exposures and CRC were likely to be 
causal.  
 
The associations of each unrestricted allele score for respective target lipid traits are shown 
in Figure 1. A positive correlation between variants associated with higher risk levels of TC 
and CRC was observed. The pooled OR meta-analysis for CRC by TC, estimated in IV analysis 
using the allele score was 1.46 per genetically instrumented SD increase in TC (95% CI: 1.20-
1.79, P = 1.68 x 10-4, test for heterogeneity between studies I2 = 6%, Phet = 0.38).  
 
The strongest reported SNP association for TC levels was provided by rs10401969 (CILP2) and 
rs12916 (HMGCR)19. To examine if the correlation between TC and CRC risk was primarily 
driven by these variants, we performed a sensitivity analysis excluding rs10401969 and 
rs12916. Omission of these two SNPs from the MR analysis did not appreciably affect our MR 
findings with results remaining significant (OR = 1.69, 95% CI: 1.25-2.28, P = 6.76 x 10-4). Albeit 
not significant, there was some support for a positive association with LDL (OR = 1.05, 95% CI: 
0.92-1.18, P = 0.49) and CRC risk, and a negative association between HDL (OR = 0.94, 95% CI: 
0.84-1.05, P = 0.27) and CRC risk. 
 
Following on from these analyses, we performed a MR based analysis of LDL, HDL and TG 
using genetic scores derived from restricted sets of SNPs. As with the unrestricted analysis, 
no significant causal effect for each of these lipid traits was observed (Supplementary Figure 
2).  
 
Finally, genetically predicted lowered TC using the HMGCR genetic risk score was associated 
with 43% reduction in CRC (OR=0.69, 95% CI: 0.49-0.99, P=0.046, Phet= I2=56%).  
 
DISCUSSION 
 
The present study strengthens a causal inference between circulating levels of TC and risk of 
developing CRC that is independent of known confounding effects. The positive correlation 
between the IV for TC and CRC risk, remained significant even after imposing a Bonferroni-
correction to account for multiple testing. It is noteworthy that none of the IV SNPs for TC 
also represent IVs for obesity26, supporting an independent relationship between TC and CRC. 
As illustrated here and in previously studies of obesity and CRC 27, 28, insulin levels and uterine 
cancer 29, and lipid levels and coronary heart disease 30 MR provides an attractive means of 
establishing causal associations. In addition to demonstrating an association between TC and 
CRC risk we found that genetic variants that mimic the effect of HMGCR inhibition were 
associated with a reduced CRC risk, supporting findings from observational epidemiological 
studies that statins have beneficial effect on the population burden of CRC.  
 
Studies in mice have shown that knocking out the cell surface cholesterol-sensing receptor 
gene NPC1L1, which plays a critical role in the absorption of intestinal cholesterol, reduces 
CRC risk31. However, the biological mechanism by which cholesterol may affect CRC risk 
remains to be established. Cholesterol is thought to have multiple carcinogenic/cancer 
promoting effects at the cellular level and several mechanisms have been variously suggested, 
including the cholesterol-mediated activation of the NLRP3 inflammasome32. Since statins are 
largely retained by hepatocytes, their effect on CRC will be indirect, via HMGCR inhibition. 
Intriguingly, recent data suggests that any impact of statin therapy on CRC is by prevention of 
progression of adenomas to frank cancers rather than their development per se 33. Further 
research on the biological relationship between cholesterol and CRC is needed to address 
such a proposition.   
 
A major strength of our MR analysis is that it does not suffer from the influence of recall bias 
and confounding that affects traditional observational studies. Nevertheless, a primary 
assumption in MR is that the variants used to generate genetic scores are indeed associated 
with the exposure being examined. To ensure this was the case, we only made use of variants 
associated with each lipid trait at genome-wide significance from hypothesis-free GWAS. A 
second assumption is that variants are associated with CRC only through the exposure and 
are not confounded by shared genetic (i.e. pleiotropy). This would be revealed as an 
increasing linear relationship between SNPs and their effect size for any lipid trait and CRC 
risk; we did not observe such a relationship. Although it is not possible to exclude confounding 
by unknown confounders, the use of multiple independent variants acting through different 
pathways reduces the likelihood of confounded IV-associations. Moreover by using LD 
regression, we have been able to exclude pleiotropism on a global basis21. Finally, we only 
made use of data from individuals of European descent in the GWAS SNPs to limit potential 
bias from population stratification influencing study findings.  
 
As with any MR analysis, there are potential limitations to our findings, including the limited 
trait variance explained by genetic variants, restricting statistical power. This is especially 
relevant for null findings, since wide confidence intervals leave uncertainty over the presence 
of a causal effect. It is estimated that the SNPs from the Global Lipids Genetics Consortium 
GWAS explain approximately 8-11% of the total variation in each lipid trait19. Recent analyses 
of observational studies found higher impact on CRC for TC than LDL or TG; respective ORs 
and 95% CIs – 1.49 (1.32-1.69), 1.37 (1.11-1.69), and 1.16 (1.06-1.27) 8. Based on these data 
our MR study was well-powered to demonstrate a causal relation for TC (≈80%, stipulating a 
P-value of 0.05), but we had limited power to identify associations for other lipid traits, 
particularly TG and HDL (respective power estimates for TG, LDL and HDL being 13%, 68% and 
31%). Hence while the ORs for CRC with LDL and TG are congruous with observational studies 
34 larger studies are required to formally establish a relationship using MR. 
 
There are differences in the genomic landscapes of colonic and rectal cancers which 
presumably may reflect differences in aetiology. Unfortunately, these data were not 
uniformly collected across datasets, and we therefore did not investigate the possibility of 
differential effects of cholesterol on risk by anatomical location within the colorectum35.  
 
In conclusion, this study provides evidence for a causal role of higher TC levels in the aetiology 
of CRC. Hence our findings encouragingly support the overall findings of past observational 
studies. Our limited power to further refine the relationship between lipid profile and CRC 
provides a motivational for larger MR studies, which will benefit from enhanced statistical 
power to demonstrate relationships for the spectrum of colorectal neoplasia. Irrespective of 
the exact functional basis of the association between TC and CRC risk, reducing 
hyperlipidaemia is an important target for primary prevention of CRC in the population. Our 
analysis therefore supports the hypothesis that the increasing use of statins in the population 
for prevention of cardiovascular disease will have the added bonus of reducing the burden of 
CRC.  
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FIGURES and TABLES 
Figure 1: Meta-analysis odds ratios (OR) for colorectal cancer per unit increase in genetic 
risk score (SD trait) for each lipid trait. TC: Total cholesterol, TG: Triglyceride, LDL: low density 
lipoprotein, HDL: high density lipoprotein; Horizontal lines: 95% Confidence Intervals (95% 
CI). Phet: P-value for heterogeneity; I2: proportion of the total variation due to heterogeneity. 
Box: OR point estimate; its area is proportional to the weight of the study. Diamond: overall 
summary estimate, with confidence interval given by its width. Vertical line: null value 
(OR = 1.0). 
 
 
 
Table 1: Summary of the seven genome-wide association studies of colorectal cancer (9,254 cases and 18,386) 
Series Study setting Study centre Sampling No. cases No. controls 
CCFR1 Colon Cancer Family Registry University of Southern California Recently diagnosed cases reported to population-based cancer registries 
in the USA (Seattle Familial Colorectal Cancer Registry). Canada (Ontario 
Familial Cancer Registry) and Australia (Australasian Colorectal Cancer 
Family Study). Population-based controls. 
1,290 1,055 
CCFR2 Colon Cancer Family Registry University of Southern California Recently diagnosed cases reported to population-based cancer registries 
in the USA (Seattle Familial Colorectal Cancer Registry, Mayo Clinic 
Cooperative Family Registry for Colon Cancer Studies, USC Consortium 
Colorectal Cancer Family Registry, University of Hawaii Colorectal Cancer 
Family Registry). Canada (Ontario Familial Cancer Registry) Australia 
(Australasian Colorectal Cancer Family Study). Unaffected family 
controls. 
796 2,236 
COIN COIN trial: Multicentre study of cetuximab 
and other therapies in metastatic CRC. 
Controls were unselected blood donors 
Cardiff University Cases recruited as a clinical-based series and controls as population-
based series. 
2,244 2,162 
FINLAND Finnish Colorectal Cancer Predisposition 
Study  
Helsinki University Cases requited through Finnish Hospitals and Finnish Cancer Registry. 
Population-based controls from FINRISK, Health 2000, Finnish Twin 
Cohort and Helsinki Birth Cohort Studies. 
1,172 8,266 
UK1 CORGI (colorectal Tumour Gene 
Identification Consortium) 
Oxford University Cases enriched for family history of CRC, ascertained through UK clinical 
genetics clinics. Spouse controls with no personal history or family 
history of CRC.  
940 965 
Scotland1 COGS (Colorectal Cancer Susceptibility 
Study) 
Edinburgh University Scottish population-based incidence cases aged <55 at diagnosis. 
Population-based controls frequency matched by area of residence. 
Scotland 
1,012 1,012 
VQ58 Cases: VICTOR, post treatment stager of a 
phase III, randomised trial of rofecoxib 
(VIOXX) in patients after potentially 
curative therapy. QUASAR2, multi-centre 
study of capectibine±bevacizumb as 
adjuvant treatment. 1958 Birth Cohort 
controls 
Oxford University Cases recruited as a clinical-based series and controls as population-
based series. 
1,800 2,690 
  
Table 2: Testing for global and instrumental-specific pleiotropism. Point estimates, 
confidence intervals, and P-values from linkage disequilibrium (LD) regression analysis, and 
MR-Egger methods. For MR-Egger, the intercept represents the average pleiotropic effect; an 
intercept significantly different from zero implies directional pleiotropy. 
 
LD regression results   
Trait Heritability estimate Genetic correlation Standard error P-value 
TC 0.2408 0.049 0.0635 0.4402 
TG 0.2939 0.0322 0.0639 0.6143 
LDL 0.2122 0.0729 0.066 0.2696 
HDL 0.2499 -0.0603 0.563 0.2834 
 
MR-Egger regression results   
 Trait  
 
Estimate 
Corrected 
standard error 
CI lower CI upper P-value 
TC intercept 1.11x10-2 1.25x10-2 -1.42x10-2 3.64x10-2 0.38 
 slope 0.16 0.33 -0.51 0.83 0.64 
TG intercept -1.13x10-2 1.10x10-2 -3.38x10-2 1.12x10-2 0.31 
 slope 5.65x10-2 0.17 -0.30 0.42 0.75 
LDL intercept -3.41x10-3 7.67x10-3 -1.91x10-2 1.23x10-2 0.66 
 slope 0.10 0.11 -0.11 0.32 0.34 
HDL intercept 2.23x10-3 5.58x10-3 -8.94x10-3 1.34x10-2 0.69 
 slope -0.11 0.11 -0.32 0.11 0.31 
 
 
 
